Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Preventing Epilepsy After Traumatic Brain Injury With Topiramate (PEPTO)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2008 by University of Pennsylvania.
Recruitment status was:  Recruiting
Information provided by:
University of Pennsylvania Identifier:
First received: January 11, 2008
Last updated: January 22, 2008
Last verified: January 2008
Our hypothesis is that topiramate will reduce acute seizures after traumatic brain injury and will help prevent the development of epilepsy after traumatic brain injury.

Condition Intervention Phase
Traumatic Brain Injury
Drug: topiramate
Drug: phenytoin
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Preventing Epilepsy After Traumatic Brain Injury: A Pilot, Single-Center Randomized Trial of Topiramate to Prevent Seizures After Moderate to Severe TBI

Resource links provided by NLM:

Further study details as provided by University of Pennsylvania:

Primary Outcome Measures:
  • Early and late seizures after traumatic brain injury [ Time Frame: 2 years ]
  • Adverse events [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • Functional recovery after traumatic brain injury [ Time Frame: 2 years ]

Estimated Enrollment: 90
Study Start Date: November 2004
Estimated Study Completion Date: February 2009
Estimated Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Phenytoin 20mg/kg load, then Topiramate, 100 mg twice daily, starting at 24 hours post-TBI for 6 days.
Drug: topiramate
100 twice per day for 6 days after loading dose of phenytoin
Experimental: 2
topiramate for 3 months after loading dose of phenytoin
Drug: topiramate
100 mg twice per day for 3 months
Placebo Comparator: 3
Phenytoin 20 mg/kg as loading dose than 300 mg/day for total of 7 days
Drug: phenytoin
loading dose of 20 mg/kg and then 300 mg/day for total of 7 days

Detailed Description:
Traumatic brain injury (TBI) causes epilepsy in up to 30% of civilian and 50% of military head injuries, exacerbating chronic neurological disability. There is currently no method for preventing epilepsy after TBI. We hypothesize that the new antiepileptic drug, topiramate (TPM), will (1) reduce acute seizures and prevent the development of epilepsy following TBI and (2) improve neurological recovery. We propose to perform a pilot clinical trial to develop the necessary infrastructure for larger scale randomized clinical trials to test TPM, and, possibly, other new antiepileptic drugs with neuroprotective properties, for their ability to prevent epilepsy after TBI. Subjects with TBI will be randomized within 24 hours to one of three groups: 1) TPM for one week, 2) TPM for three months, or 3) phenytoin for one week. Subjects will be followed for two years for the development of seizures and for neurological outcome. Serial EEGs and MRIs will be performed to explore potential mechanisms for the development of epilepsy after TBI. These new tools for the clinical study of epilepsy prevention, and neuroprotection in general, will be developed that can be applied to a wide variety of studies and which will facilitate future research in this critical area.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Moderate to severe traumatic brain injury, defined as one or more of the following: penetrating head wound seizure within the first hour after injury intracerebral hematoma or cortical contusion subdural or epidural hematoma Glasgow Coma Score <= 12 or motor score 1-5 (if intubated). Patients who have been pharmacologically paralyzed will be evaluated after the paralytic has worn off or been pharmacologically reversed depressed skull fracture requirement for emergent neurosurgical procedure
  2. Time since TBI less than 24 hours
  3. Age greater than or equal to 18 years
  4. Subject capable of giving informed consent or have an acceptable surrogate capable of giving consent on the subject's behalf. -

Exclusion Criteria:

  1. Known prior history of epilepsy or unprovoked seizures. Patients with a history of acute symptomatic seizures (e.g. febrile seizure, alcohol withdrawal seizure) will not be excluded
  2. Administration of an antiepileptic drug before enrollment
  3. History of allergy to topiramate or phenytoin
  4. Pregnancy or breast-feeding. Women of childbearing potential must have a negative pregnancy test (urine pregnancy test or serum beta-HCG) before randomization
  5. Compromised renal function with serum creatinine > 2
  6. Severe concurrent illness with life expectancy <6 months
  7. Treatment with another investigational agent for TBI
  8. Unable to take medications orally and contraindication to placement of nasogastric tube.
  9. Irreversibly fatal TBI

    1. All four findings: Glasgow Coma Score = 3, no pupillary reaction, age > 45 years, and severe coagulopathy OR
    2. Severe brainstem lesion on neuroimaging studies
  10. Patients with a history of kidney stones or glaucoma.
  11. Inability to maintain adequate fluid intake while taking topiramate.
  12. Patients whose TBI is a result of self inflicted injury
  13. Patient's who are currently using illicit drugs -
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00598923

Contact: Kelly S Maxwell 215 614 0520

United States, Pennsylvania
Hospital of the University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
Principal Investigator: Marc A Dichter, MD, PhD         
Sub-Investigator: Susan T Herman, MD         
Sponsors and Collaborators
University of Pennsylvania
Principal Investigator: Marc A Dichter, MD, PhD University of Pennsylvania
  More Information

Responsible Party: Dr. Marc A. Dichter, University of Pennsylvania Identifier: NCT00598923     History of Changes
Other Study ID Numbers: PR043514
Study First Received: January 11, 2008
Last Updated: January 22, 2008

Keywords provided by University of Pennsylvania:
traumatic brain injury

Additional relevant MeSH terms:
Wounds and Injuries
Brain Injuries
Brain Diseases
Craniocerebral Trauma
Trauma, Nervous System
Central Nervous System Diseases
Nervous System Diseases
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP1A2 Inducers
Cytochrome P-450 Enzyme Inducers
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs
Anti-Obesity Agents processed this record on April 28, 2017